A multicenter, open-label, non-interventional study evaluates the safety and tolerability of oral Dimolegin® (60 mg once daily) for thromboprophylaxis in hospitalized adults (≥18 years) with moderate COVID-19 in real clinical pratice. The primary objective is to assess safety and tolerability of Dimolegin® in preventing thrombotic complications.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-19; most recent amendment 2026-01-15.